MicrobeWorld App

appsquarebannerad200x200

Microbes After Hours

MWbannerEbola

Click for more "Microbes After Hours" videos

Join MicrobeWorld

Subscribe via Email

subscribe

Featured Image

Featured Video

Ebola Virus explained

Supporters

ASM House 200X200

Innovative vaccine in trial for advanced ovarian cancer

A clinical trial of an innovative vaccine is occurring. The vaccine could offer hope to patients with advanced ovarian cancer. The vaccine, which is derived from the patient's tumor cells, is designed to jumpstart the patient's immune system to attack and kill cancer cells.

Ovarian cancer is the fifth leading cause of cancer-related deaths in American women, causing more than 15,000 deaths per year. In about two-thirds of patients, the cancer has spread beyond the ovaries to other parts of the body by the time it is diagnosed. Current treatment is to surgically remove as much of the tumor as possible, followed by chemotherapy. But despite improvements in surgical techniques and chemotherapy, most patients with advanced ovarian cancer relapse at some point. The five-year survival rate for patients with advanced ovarian cancer is less than 30%. There is no cure for patients with relapsed or metastatic ovarian cancer who have failed first-line treatment.

The vaccine trial, conducted by Loyola University Medical Center in Maywood, Illinois, is enrolling patients with advanced ovarian cancer. Following surgery, tumor cells are dissolved in a solution called lysate, which contains fragments of the cancer cells. The lysate is joined with some of the patient's immune system cells to create the vaccine. (The immune system cells used in the vaccine, called dendritic cells, are taken from the patient's bloodstream.)
 
 

Comments (0)

Collections (0)

 

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use